Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
2
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
2
×
san francisco top stories
abbvie
allergan aesthetics
alzheimer's disease
astrazeneca
athira pharma
attralus
biontech
biotech
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
cancer
cancer drugs
chiesi farmaceutici
cholestatic liver diseases
cholesterol
click therapeutics
clinical trials
covid-19
cullinan oncology
cystic fibrosis
daniel o'day
data
deals
detroit blog main
detroit top stories
diabetic macular edema
diagnostics
dogma therapeutics
dyne therapeutics
What
ceo
drug
2
×
week
2
×
aces
acquisitions
announced
big
biggest
bio
build
buy
cholesterol
company’s
daniel
debut
dyne’s
flexible
gilead
inclisiran
key
lowering
meant
medco
medicine
medicines
microbiome
moves
nasdaq
open
openly
o’day
passed
pipeline
pricing
roundup
sciences
scores
seagen
spoken
taken
Language
unset
Current search:
drug
×
amgen
×
" san francisco blog main "
×
week
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing